RxDoctor Payments Data

Reza Azar, MD

Cardiovascular Disease · Miami, FLNPI 1043236862

Payments from drug & device makers

$825in general payments, 2019–2025

Across 37 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$203
  • Esperion Therapeutics, Inc.$129
  • Novo Nordisk$109
  • Pfizer$95
  • Boston Scientific$91
  • Johnson & Johnson$47
  • plus $152 from 6 others

What the payments were for

  • Food & beverage$825100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$825 in reported general payments places this provider in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$72,766
Medicare patients
620
Services billed
1,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$103,724
XareltoRivaroxaban51$57,040
OzempicSemaglutide34$35,049
JanuviaSitagliptin Phosphate23$33,273
JardianceEmpagliflozin17$24,512
EntrestoSacubitril/Valsartan19$24,438
TradjentaLinagliptin11$4,505
LivaloPitavastatin Calcium13$4,226
Fluticasone Propionate HfaFluticasone Propionate13$3,495
Metoprolol Succinate176$2,842
Telmisartan39$2,162
Rosuvastatin Calcium143$2,148
Nebivolol Hcl19$1,722
Digoxin82$1,685
Ezetimibe47$1,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$95$103,72478 claims
Johnson & JohnsonXarelto$47$57,04051 claims
Novo NordiskOzempic$109$35,04934 claims
NovartisEntresto$19$24,43819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →